The primitive ontology strategy to quantum mechanics seeks to account for quantum phenomena by way of a distribution of matter in three-dimensional area (or four-dimensional spacetime) and a regulation of nature that describes its temporal growth. This strategy to explaining quantum phenomena is appropriate with both a Humean or powerist account of legal guidelines.
On this paper, I provide a powerist ontology during which the regulation is specified by Bohmian mechanics for a worldwide configuration of particles. Not like in different powerist ontologies, nevertheless, this regulation isn’t grounded in a structural energy that’s instantiated by the worldwide configuration. As an alternative, I mix the primitive ontology strategy with Aristotle’s doctrine of hylomorphism to create a brand new metaphysical mannequin, during which the cosmos is a hylomorphic substance with an intrinsic energy to choreograph the trajectories of the particles.
Use of a modular ontology and a semantic annotation device to explain the care pathway of sufferers with amyotrophic lateral sclerosis in a coordination community
The target of this examine was to explain the care pathway of sufferers with amyotrophic lateral sclerosis (ALS) primarily based on real-life textual knowledge from a regional coordination community, the Ile-de-France ALS community. This coordination community gives look after 92% of sufferers recognized with ALS residing in Ile-de-France. We developed a modular ontology (OntoPaRON) for the automated processing of those unstructured textual knowledge. OntoPaRON has completely different modules: the core, medical, socio-environmental, coordination, and consolidation modules.
Our strategy was distinctive in its creation of totally outlined ideas at completely different ranges of the modular ontology to handle particular matters regarding healthcare trajectories. We additionally created a semantic annotation device particular to the French language and the specificities of our corpus, the Ontology-Primarily based Semantic Annotation Module (OnBaSAM), utilizing the OntoPaRON ontology as a reference. We used these instruments to annotate the data of 928 sufferers robotically. The semantic (qualitative) annotations of the ideas have been remodeled into quantitative knowledge.
By utilizing these pipelines we have been in a position to remodel unstructured textual knowledge into structured quantitative knowledge. Primarily based on knowledge processing, semantic annotations, sociodemographic knowledge for the affected person and medical variables, we discovered that the necessity and demand for human and technical help rely on the preliminary type of the illness, the motor state, and the affected person age. The presence of exhaustion in care administration, is said to the affected person’s motor and cognitive state.
The Finish of a Classical Ontology for Quantum Mechanics?
On this paper, I argue that the Shrapnel-Costa no-go theorem undermines the final remaining viability of the view that the basic ontology of quantum mechanics is basically classical: that’s, the view that bodily actuality is underpinned by objectively actual, counterfactually particular, uniquely spatiotemporally outlined, native, dynamical entities with determinate valued properties, and the place usually ‘quantum’ behaviour emerges as a operate of our personal in-principle ignorance of such entities.
Name this view Einstein-Bell realism. One can present that the causally symmetric native hidden variable strategy to deciphering quantum concept is essentially the most pure interpretation that follows from Einstein-Bell realism, the place causal symmetry performs a big function in circumventing the nonclassical penalties of the standard no-go theorems. Nevertheless, Shrapnel and Costa argue that unique causal constructions, similar to causal symmetry, are incapable of explaining quantum behaviour as arising on account of noncontextual ontological properties of the world. That is significantly worrying for Einstein-Bell realism and classical ontology.
Within the first occasion, the apparent consequence of the theory is an easy rejection of Einstein-Bell realism. Nevertheless, greater than this, I argue that, even the place there appears to be a chance of accounting for contextual ontic variables inside a causally symmetric framework, the price of such an account undermines a key benefit of causal symmetry: that accepting causal symmetry is extra economical than rejecting a classical ontology. Both approach, it appears like we should always surrender on classical ontology.
Recombinant Humanp21 Recombinant Protein |
ProSci |
TWEAK, recombinant / TNFSF12, recombinant (Human) |
PHOENIX PEPTIDE |
TAGLN Recombinant Protein (Rat) (Recombinant- Tag) |
ABM |
TAGLN2 Recombinant Protein (Rat) (Recombinant Tag) |
ABM |
TAGLN3 Recombinant Protein (Rat) (Recombinant Tag) |
ABM |
CellO: complete and hierarchical cell kind classification of human cells with the Cell Ontology
Cell kind annotation is a elementary activity within the evaluation of single-cell RNA-sequencing knowledge. On this work, we current CellO, a machine learning-based device for annotating human RNA-seq knowledge with the Cell Ontology. CellO allows correct and standardized cell kind classification of cell clusters by contemplating the wealthy hierarchical construction of identified cell varieties. Moreover, CellO comes pre-trained on a complete knowledge set of human, wholesome, untreated main samples within the Sequence Learn Archive.
CellO’s complete coaching set allows it to expire of the field on various cell varieties and achieves aggressive and even superior efficiency when in comparison with present state-of-the-art strategies. Lastly, CellO’s linear fashions are simply interpreted, thereby enabling exploration of cell-type-specific expression signatures throughout the ontology. To this finish, we additionally current the CellO Viewer: an internet software for exploring CellO’s fashions throughout the ontology.
Recombinant Humanp21 Recombinant Protein |
92-035 |
TWEAK, recombinant / TNFSF12, recombinant (Human) |
054-85 |
TAGLN Recombinant Protein (Rat) (Recombinant- Tag) |
RP232205 |
TAGLN2 Recombinant Protein (Rat) (Recombinant Tag) |
RP232208 |
TAGLN3 Recombinant Protein (Rat) (Recombinant Tag) |
RP232211 |
Ontology-Mediated Querying with Horn Description Logics
An ontology-mediated question (OMQ) consists of a database question paired with an ontology. When evaluated on a database, an OMQ returns not solely the solutions which can be already within the database, but additionally these solutions that may be obtained by way of logical reasoning utilizing guidelines from ontology. There are a lot of open questions concerning the complexities of issues associated to OMQs. Motivated by way of ontologies in observe, new reasoning issues which have by no means been thought-about within the context of ontologies turn out to be related, since they’ll enhance the usability of ontology enriched methods.
This thesis offers with varied reasoning issues that emerge from ontology-mediated querying and it investigates the computational complexity of those issues. We deal with ontologies formulated in Horn description logics, that are a preferred alternative for ontologies in observe. Specifically, the thesis offers outcomes concerning the info complexity of OMQ analysis by fully classifying complexity and rewritability questions for OMQs primarily based on an EL ontology and a conjunctive question.
Rcn3 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
TL502888 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
RCN2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV695479 |
ABM |
1.0 ug DNA |
EUR 616.8 |
RCN2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV695483 |
ABM |
1.0 ug DNA |
EUR 616.8 |
RCN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV647263 |
ABM |
1.0 ug DNA |
EUR 616.8 |
RCN1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV647267 |
ABM |
1.0 ug DNA |
EUR 616.8 |
RCN2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
LV695484 |
ABM |
1.0 ug DNA |
EUR 616.8 |
RCN1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
LV792577 |
ABM |
1.0 ug DNA |
EUR 379.2 |
RCN1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
LV647268 |
ABM |
1.0 ug DNA |
EUR 616.8 |
RCN1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
LV792578 |
ABM |
1.0 ug DNA |
EUR 379.2 |
RCN1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
LV742685 |
ABM |
1.0 ug DNA |
Ask for price |
RCN1P1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
LV742689 |
ABM |
1.0 ug DNA |
Ask for price |
RCN1P2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
LV773765 |
ABM |
1.0 ug DNA |
EUR 1173.6 |
RCN1P2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
LV773769 |
ABM |
1.0 ug DNA |
EUR 1173.6 |
RCN1P1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
LV742690 |
ABM |
1.0 ug DNA |
Ask for price |
RCN1P2 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
LV773770 |
ABM |
1.0 ug DNA |
EUR 1173.6 |
RCN2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
LV695480 |
ABM |
1.0 ug DNA |
EUR 616.8 |
RCN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
LV647264 |
ABM |
1.0 ug DNA |
EUR 616.8 |
RCN2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
LV695481 |
ABM |
1.0 ug DNA |
EUR 686.4 |
RCN2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
LV695482 |
ABM |
1.0 ug DNA |
EUR 686.4 |
RCN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
LV647265 |
ABM |
1.0 ug DNA |
EUR 686.4 |
RCN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
LV647266 |
ABM |
1.0 ug DNA |
EUR 686.4 |
RCN1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
LV792576 |
ABM |
1.0 ug DNA |
EUR 448.8 |
RCN1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
LV742686 |
ABM |
1.0 ug DNA |
Ask for price |
RCN1P2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
LV773766 |
ABM |
1.0 ug DNA |
EUR 1173.6 |
RCN1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
LV742687 |
ABM |
1.0 ug DNA |
Ask for price |
RCN1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
LV742688 |
ABM |
1.0 ug DNA |
Ask for price |
RCN1P2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
LV773767 |
ABM |
1.0 ug DNA |
EUR 1243.2 |
RCN1P2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
LV773768 |
ABM |
1.0 ug DNA |
EUR 1243.2 |
Rcn1 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
TL707120 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
Rcn2 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
TL709941 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
Rcn2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
TL510567 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
RCN2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
TL309888 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
RCN1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
TL309889 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
Rcn1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
TL501873 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
Rcn3 ORF Vector (Rat) (pORF) |
ORF074653 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Rcn3 ORF Vector (Mouse) (pORF) |
ORF055803 |
ABM |
1.0 ug DNA |
EUR 607.2 |
RCN3 ORF Vector (Human) (pORF) |
ORF008695 |
ABM |
1.0 ug DNA |
EUR 114 |
CD Lentiviral Vector |
LV678 |
ABM |
10 μg |
EUR 950 |
Green Kit. Baculovirus GFP vector. |
K20 |
AB Vector LLC |
1 Kit |
EUR 695 |
|
Description: Protein expression |
ProGreen. Baculovirus GFP marker vector. |
A1 |
AB Vector LLC |
25 ul |
EUR 420 |
|
Description: Protein expression |
RCN3 Protein Vector (Rat) (pPM-C-HA) |
PV298612 |
ABM |
500 ng |
EUR 723.6 |
RCN3 Protein Vector (Rat) (pPB-C-His) |
PV298610 |
ABM |
500 ng |
EUR 723.6 |
RCN3 Protein Vector (Rat) (pPB-N-His) |
PV298611 |
ABM |
500 ng |
EUR 723.6 |
RCN3 Protein Vector (Rat) (pPM-C-His) |
PV298613 |
ABM |
500 ng |
EUR 723.6 |
RCN3 Protein Vector (Mouse) (pPM-C-HA) |
PV223212 |
ABM |
500 ng |
EUR 723.6 |
RCN3 Protein Vector (Human) (pPM-C-HA) |
PV034779 |
ABM |
500 ng |
EUR 394.8 |
RCN3 Protein Vector (Mouse) (pPB-C-His) |
PV223210 |
ABM |
500 ng |
EUR 723.6 |
RCN3 Protein Vector (Mouse) (pPB-N-His) |
PV223211 |
ABM |
500 ng |
EUR 723.6 |
RCN3 Protein Vector (Mouse) (pPM-C-His) |
PV223213 |
ABM |
500 ng |
EUR 723.6 |
RCN3 Protein Vector (Human) (pPB-C-His) |
PV034777 |
ABM |
500 ng |
EUR 394.8 |
RCN3 Protein Vector (Human) (pPB-N-His) |
PV034778 |
ABM |
500 ng |
EUR 394.8 |
RCN3 Protein Vector (Human) (pPM-C-His) |
PV034780 |
ABM |
500 ng |
EUR 394.8 |
dCas9-KRAB Lentiviral Vector |
K203 |
ABM |
10 ug |
EUR 165 |
Description: N/A |
Cas9 Nickase Lentiviral Vector |
K005 |
ABM |
10 ug |
EUR 135 |
Description: N/A |
RCN3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
TL302055V |
Origene Technologies GmbH |
500 ul each |
Ask for price |
Rcn3 - Rat shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
TL701091V |
Origene Technologies GmbH |
500 ul each |
Ask for price |
Rcn3 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
TL502888V |
Origene Technologies GmbH |
500 ul each |
Ask for price |
Cas9 Nuclease Lentiviral Vector |
K002 |
ABM |
10 ug |
EUR 135 |
Description: N/A |
dCas9-DNMT3A Lentiviral Vector |
K091 |
ABM |
10 µg, Titer: N/A |
EUR 395 |
Description: N/A |
dCas9-TET1CD Lentiviral Vector |
K096 |
ABM |
10 µg, Titer: N/A |
EUR 395 |
Description: N/A |
ProEasy. Vector for easy construction of recombinant baculoviruses. |
A10S |
AB Vector LLC |
25 ul |
EUR 695 |
|
Description: Protein expression |
pAB-bee. Baculovirus plasmid vector for secreted and transmembrane proteins. |
B3 |
AB Vector LLC |
50 ul |
EUR 495 |
|
Description: Protein expression |
Cas9 Double Mutant Lentiviral Vector |
K012 |
ABM |
10 ug |
EUR 395 |
Description: N/A |
ProFold-PDI. Baculovirus chaperone vector for expression of cysteine-rich proteins. |
A7 |
AB Vector LLC |
25 ul |
EUR 830 |
|
Description: Protein expression |
ProFold-C2. Baculovirus chaperone vector for expression of cytoplasmic and nuclear proteins. |
A3 |
AB Vector LLC |
25 ul |
EUR 830 |
|
Description: Protein expression |
ProFold-ER1. Baculovirus chaperone vector for expression of secreted and membrane proteins. |
A4 |
AB Vector LLC |
25 ul |
EUR 830 |
|
Description: Protein expression |
ProFold-C1. Baculovirus chaperone vector for expression of cytoplasmic and nuclear proteins. |
A2 |
AB Vector LLC |
25 ul |
EUR 830 |
|
Description: Protein expression |
Luciferase-mCherry Lentiviral Vector (CMV) |
LV010138 |
ABM |
1.0 μg |
EUR 230 |
ESR1 Lentiviral Vector (Human) (pLenti-II) |
LV010008 |
ABM |
1.0 ug DNA |
EUR 379.2 |
pLenti-GFP Lentiviral Control Vector |
LTV-400 |
Cell Biolabs |
100 µL |
EUR 420 |
pLenti-GFP Lentiviral Control Vector |
MBS168202-01mL |
MyBiosource |
0.1mL |
EUR 660 |
pLenti-GFP Lentiviral Control Vector |
MBS168202-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2795 |
pLenti-MCS Lentiviral Expression Vector |
LV000 |
ALSTEM |
10 µg |
EUR 416.5 |
pSMPUW-Neo Lentiviral Expression Vector |
MBS169522-001mg |
MyBiosource |
0.01mg |
EUR 665 |
pSMPUW-Neo Lentiviral Expression Vector |
MBS169522-5x001mg |
MyBiosource |
5x0.01mg |
EUR 2825 |
pSMPUW-Neo Lentiviral Expression Vector |
VPK-213 |
Cell Biolabs |
10 µg |
EUR 424 |
pSMPUW-Puro Lentiviral Expression Vector |
MBS169521-001mg |
MyBiosource |
0.01mg |
EUR 665 |
pSMPUW-Puro Lentiviral Expression Vector |
MBS169521-5x001mg |
MyBiosource |
5x0.01mg |
EUR 2825 |
pSMPUW-Puro Lentiviral Expression Vector |
VPK-212 |
Cell Biolabs |
10 µg |
EUR 424 |
pSMPUW-MNDnLacZ Lentiviral Control Vector |
LTV-402 |
Cell Biolabs |
10 µg |
EUR 741.6 |
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
pSMPUW-Hygro Lentiviral Expression Vector |
MBS169523-001mg |
MyBiosource |
0.01mg |
EUR 665 |
pSMPUW-Hygro Lentiviral Expression Vector |
MBS169523-5x001mg |
MyBiosource |
5x0.01mg |
EUR 2825 |
pSMPUW-Hygro Lentiviral Expression Vector |
VPK-214 |
Cell Biolabs |
10 µg |
EUR 505 |
XK Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV658357 |
ABM |
1.0 ug DNA |
EUR 818.4 |
XK Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV658361 |
ABM |
1.0 ug DNA |
EUR 818.4 |
GC Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV658465 |
ABM |
1.0 ug DNA |
EUR 818.4 |
GC Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV658469 |
ABM |
1.0 ug DNA |
EUR 818.4 |
G4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV659323 |
ABM |
1.0 ug DNA |
EUR 616.8 |
G4 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV659327 |
ABM |
1.0 ug DNA |
EUR 616.8 |
FH Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV666085 |
ABM |
1.0 ug DNA |
EUR 818.4 |
FH Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV666089 |
ABM |
1.0 ug DNA |
EUR 818.4 |
F7 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV666001 |
ABM |
1.0 ug DNA |
EUR 818.4 |
F7 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV666005 |
ABM |
1.0 ug DNA |
EUR 818.4 |
F9 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV667969 |
ABM |
1.0 ug DNA |
EUR 818.4 |
F9 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV667973 |
ABM |
1.0 ug DNA |
EUR 818.4 |
F3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV693439 |
ABM |
1.0 ug DNA |
EUR 616.8 |
F3 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV693443 |
ABM |
1.0 ug DNA |
EUR 616.8 |
SI Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV694363 |
ABM |
1.0 ug DNA |
EUR 3415.2 |
SI Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV694367 |
ABM |
1.0 ug DNA |
EUR 3415.2 |
MB Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV694681 |
ABM |
1.0 ug DNA |
EUR 616.8 |
MB Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV694685 |
ABM |
1.0 ug DNA |
EUR 616.8 |
PC Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV696073 |
ABM |
1.0 ug DNA |
EUR 1626 |
PC Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV696077 |
ABM |
1.0 ug DNA |
EUR 1626 |
IK Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV696211 |
ABM |
1.0 ug DNA |
EUR 818.4 |
IK Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV696215 |
ABM |
1.0 ug DNA |
EUR 818.4 |
C6 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV673381 |
ABM |
1.0 ug DNA |
EUR 1626 |
C6 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV673385 |
ABM |
1.0 ug DNA |
EUR 1626 |
KL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV673531 |
ABM |
1.0 ug DNA |
EUR 1626 |
KL Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV673535 |
ABM |
1.0 ug DNA |
EUR 1626 |
TF Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV652363 |
ABM |
1.0 ug DNA |
EUR 1626 |
TF Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV652367 |
ABM |
1.0 ug DNA |
EUR 1626 |
C2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV655195 |
ABM |
1.0 ug DNA |
EUR 1626 |
C2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV655199 |
ABM |
1.0 ug DNA |
EUR 1626 |
HP Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV683065 |
ABM |
1.0 ug DNA |
EUR 818.4 |
HP Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV683069 |
ABM |
1.0 ug DNA |
EUR 818.4 |
F2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV698257 |
ABM |
1.0 ug DNA |
EUR 818.4 |
F2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV698261 |
ABM |
1.0 ug DNA |
EUR 818.4 |
HR Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV698527 |
ABM |
1.0 ug DNA |
EUR 1626 |
HR Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV698531 |
ABM |
1.0 ug DNA |
EUR 1626 |
TH Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV699655 |
ABM |
1.0 ug DNA |
EUR 818.4 |
TH Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV699659 |
ABM |
1.0 ug DNA |
EUR 818.4 |
Qk Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV686425 |
ABM |
1.0 ug DNA |
EUR 616.8 |
Qk Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV686429 |
ABM |
1.0 ug DNA |
EUR 616.8 |
C9 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV677989 |
ABM |
1.0 ug DNA |
EUR 818.4 |
C9 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV677993 |
ABM |
1.0 ug DNA |
EUR 818.4 |
TG Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV679015 |
ABM |
1.0 ug DNA |
EUR 4963.2 |
TG Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV679019 |
ABM |
1.0 ug DNA |
EUR 4963.2 |
CS Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV679231 |
ABM |
1.0 ug DNA |
EUR 818.4 |
CS Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV679235 |
ABM |
1.0 ug DNA |
EUR 818.4 |
AR Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV675175 |
ABM |
1.0 ug DNA |
EUR 1626 |
AR Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV675179 |
ABM |
1.0 ug DNA |
EUR 1626 |
CP Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV676159 |
ABM |
1.0 ug DNA |
EUR 1626 |
CP Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV676163 |
ABM |
1.0 ug DNA |
EUR 1626 |
C3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV688795 |
ABM |
1.0 ug DNA |
EUR 3117.6 |
C3 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV688799 |
ABM |
1.0 ug DNA |
EUR 3117.6 |
GK Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV688915 |
ABM |
1.0 ug DNA |
EUR 818.4 |
GK Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV688919 |
ABM |
1.0 ug DNA |
EUR 818.4 |
N5 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV626671 |
ABM |
1.0 ug DNA |
EUR 616.8 |
N5 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV626675 |
ABM |
1.0 ug DNA |
EUR 616.8 |
F5 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV628711 |
ABM |
1.0 ug DNA |
EUR 3850.8 |
F5 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV628715 |
ABM |
1.0 ug DNA |
EUR 3850.8 |
F8 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV648325 |
ABM |
1.0 ug DNA |
EUR 4111.2 |
F8 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV648329 |
ABM |
1.0 ug DNA |
EUR 4111.2 |
T Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV639319 |
ABM |
1.0 ug DNA |
EUR 818.4 |
T Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV639323 |
ABM |
1.0 ug DNA |
EUR 818.4 |
EOS Lentiviral Vector (PL-SIN-EOS-C(3)-EiP) |
LV028858 |
ABM |
1.0 µg DNA |
EUR 215 |
EOS Lentiviral Vector (PL-SIN-EOS-S(4)-EiP) |
LV028859 |
ABM |
1.0 ug DNA |
EUR 215 |
UBD Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV657385 |
ABM |
1.0 ug DNA |
EUR 616.8 |
UBD Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV657389 |
ABM |
1.0 ug DNA |
EUR 616.8 |
MLN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV657391 |
ABM |
1.0 ug DNA |
EUR 616.8 |
MLN Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV657395 |
ABM |
1.0 ug DNA |
EUR 616.8 |
JTB Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV657625 |
ABM |
1.0 ug DNA |
EUR 616.8 |
JTB Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV657629 |
ABM |
1.0 ug DNA |
EUR 616.8 |
BMF Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV657703 |
ABM |
1.0 ug DNA |
EUR 616.8 |
BMF Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV657707 |
ABM |
1.0 ug DNA |
EUR 616.8 |
IVL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV657751 |
ABM |
1.0 ug DNA |
EUR 818.4 |
IVL Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV657755 |
ABM |
1.0 ug DNA |
EUR 818.4 |
MGP Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV657865 |
ABM |
1.0 ug DNA |
EUR 616.8 |
MGP Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV657869 |
ABM |
1.0 ug DNA |
EUR 616.8 |
ELN Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV658267 |
ABM |
1.0 ug DNA |
EUR 1626 |
ELN Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV658271 |
ABM |
1.0 ug DNA |
EUR 1626 |
SET Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV658291 |
ABM |
1.0 ug DNA |
EUR 616.8 |
SET Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV658295 |
ABM |
1.0 ug DNA |
EUR 616.8 |
FAU Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV658567 |
ABM |
1.0 ug DNA |
EUR 616.8 |
FAU Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
LV658571 |
ABM |
1.0 ug DNA |
EUR 616.8 |
C4B Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
LV658867 |
ABM |
1.0 ug DNA |
EUR 3241.2 |
Moreover, the query-by-example downside, and the expressibility and verification downside in ontology-based knowledge entry are launched and investigated.